Activity

  • Software Simplifies Technology Transfer

    Jim Cahill
    The life sciences marketplace is changing faster than nearly any other industry. Gone are the days when companies focus on a single treatment to drive their entire business. Today’s life sciences manufacturers are challenged to bring new treatments to the marketplace as quickly as possible—a trend that was magnified during the COVID-19 pandemic . As a result, innovation is key today. And innovation requires technologies…

  • Software Simplifies Technology Transfer

    Jim Cahill
    The life sciences marketplace is changing faster than nearly any other industry. Gone are the days when companies focus on a single treatment to drive their entire business. Today’s life sciences manufacturers are challenged to bring new treatments to the marketplace as quickly as possible—a trend that was magnified during the COVID-19 pandemic . As a result, innovation is key today. And innovation requires technologies…

  • Manufacturing Solutions in Personalized Healthcare

    Jim Cahill
    Update & bump: Join our experts on November 15th or 16th, 11:00 am – 5:00 pm at Emerson Solutions Center, Singapore. They are sharing more insight into how digital transformation can solve your biopharmaceutical manufacturing challenges to facilitate the pursuit of an adaptive plant. Register Now! In our Part 1 post, Manufacturing Challenges in Personalized Healthcare , Emerson’s Christian Berg explored the challenges…

  • Manufacturing Solutions in Personalized Healthcare

    Jim Cahill
    Update & bump: Join our experts on November 15th or 16th, 11:00 am – 5:00 pm at Emerson Solutions Center, Singapore. They are sharing more insight into how digital transformation can solve your biopharmaceutical manufacturing challenges to facilitate the pursuit of an adaptive plant. Register Now! In our Part 1 post, Manufacturing Challenges in Personalized Healthcare , Emerson’s Christian Berg explored the challenges…

  • Manufacturing Solutions in Personalized Healthcare

    Jim Cahill
    In our Part 1 post, Manufacturing Challenges in Personalized Healthcare , Emerson’s Christian Berg explored the challenges biopharmaceutical manufacturers face in advancing personalized healthcare. In this final part, he describes some solutions and technologies which facilitate the pursuit of the adaptive plant, as defined by the BioPhorum Digital Plant Maturity Model , required to meet these challenges. Christian…

  • Manufacturing Challenges in Personalized Healthcare

    Jim Cahill
    When we hear the phrase “personalized healthcare,” many of us think about the medicines and therapeutics focused on our specific needs that deliver treatments to dramatically improve or restore our health and extend our lives. In a Pharma Focus Asia webinar, Pursuing the Adaptive Plant to Enable Personalized Healthcare , Emerson’s Christian Berg provides a broader perspective of personalized healthcare and its challenges…

  • Manufacturing Challenges in Personalized Healthcare

    Jim Cahill
    When we hear the phrase “personalized healthcare,” many of us think about the medicines and therapeutics focused on our specific needs that deliver treatments to dramatically improve or restore our health and extend our lives. In a Pharma Focus Asia webinar, Pursuing the Adaptive Plant to Enable Personalized Healthcare , Emerson’s Christian Berg provides a broader perspective of personalized healthcare and its challenges…

  • Manufacturing Challenges in Personalized Healthcare

    Jim Cahill
    When we hear the phrase “personalized healthcare,” many of us think about the medicines and therapeutics focused on our specific needs that deliver treatments to dramatically improve or restore our health and extend our lives. In a Pharma Focus Asia webinar, Pursuing the Adaptive Plant to Enable Personalized Healthcare , Emerson’s Christian Berg provides a broader perspective of personalized healthcare and its challenges…

  • BioPhorum Cell and Gene Therapy Actors and Process Maps

    Jim Cahill
    Update & bump: Join Christian Berg on August 16, 2022 at 11am SGT ( UTC+8 ) in Pursuing the Adaptive Plant to Enable Personalized Healthcare webinar . He will be sharing more insight and the functionality of DPMM that enables your journey to an adaptive plant. Register Now ! Original post: A few weeks ago I highlighted one of the three new BioPhorum publications, MES of the Future Manifesto . Today, I’ll highlight…

  • BioPhorum Cell and Gene Therapy Actors and Process Maps

    Jim Cahill
    Update & bump: Join Christian Berg on August 16, 2022 at 11am SGT ( UTC+8 ) in Pursuing the Adaptive Plant to Enable Personalized Healthcare webinar . He will be sharing more insight and the functionality of DPMM that enables your journey to an adaptive plant. Register Now ! Original post: A few weeks ago I highlighted one of the three new BioPhorum publications, MES of the Future Manifesto . Today, I’ll highlight…

  • Adaptable Landscape Components Facilitate Digital Transformation

    Jim Cahill
    Update & bump: Join me on August 16, 2022 at 11am SGT ( UTC+8 ) in Pursuing the Adaptive Plant to Enable Personalized Healthcare webinar . I will be sharing more insight and the functionality of DPMM that enables your journey to an adaptive plant. Register Now ! Original post: The BioPhorum Operations Group (BPOG) established a digital plant maturity model (DPMM) for biopharmaceutical manufacturing to define stages…

  • Adaptable Landscape Components Facilitate Digital Transformation

    Jim Cahill
    Update & bump: Join me on August 16, 2022 at 11am SGT ( UTC+8 ) in Pursuing the Adaptive Plant to Enable Personalized Healthcare webinar . I will be sharing more insight and the functionality of DPMM that enables your journey to an adaptive plant. Register Now ! Original post: The BioPhorum Operations Group (BPOG) established a digital plant maturity model (DPMM) for biopharmaceutical manufacturing to define stages…

  • BioPhorum’s Roadmap for Speed to Market with In-Line Monitoring and Real-Time Release

    Jim Cahill
    Traditional manufacturing practices have served the biopharmaceutical industry well for years, but times are changing and a need for speed to market in life sciences while reducing manufacturing costs is putting a focus on enabling real-time release (RTR). Technologies such as advanced process control (APC), predictive analytics, in-line monitoring (ILM), and real-time release testing (RTRT) are critical to the new strategies…

  • BioPhorum’s Roadmap for Speed to Market with In-Line Monitoring and Real-Time Release

    Jim Cahill
    Traditional manufacturing practices have served the biopharmaceutical industry well for years, but times are changing and a need for speed to market in life sciences while reducing manufacturing costs is putting a focus on enabling real-time release (RTR). Technologies such as advanced process control (APC), predictive analytics, in-line monitoring (ILM), and real-time release testing (RTRT) are critical to the new strategies…

  • BioPhorum’s Roadmap for Speed to Market with In-Line Monitoring and Real-Time Release

    Jim Cahill
    Traditional manufacturing practices have served the biopharmaceutical industry well for years, but times are changing and a need for speed to market in life sciences while reducing manufacturing costs is putting a focus on enabling real-time release (RTR). Technologies such as advanced process control (APC), predictive analytics, in-line monitoring (ILM), and real-time release testing (RTRT) are critical to the new strategies…

  • BioPhorum Cell and Gene Therapy Personas and User Stories

    Jim Cahill
    Earlier I featured two recent BioPhorum publications in these posts: BioPhorum MES of the Future BioPhorum Cell and Gene Therapy Actors and Process Maps Today, I’ll highlight the third and final publication, CGT Personas and User Stories , from this release of publications. As with the other two, Emerson’s Sean Buckley was one of the primary authors, along with others from Cytiva, Dassault Systems, Novartis…

  • BioPhorum Cell and Gene Therapy Personas and User Stories

    Jim Cahill
    Earlier I featured two recent BioPhorum publications in these posts: BioPhorum MES of the Future BioPhorum Cell and Gene Therapy Actors and Process Maps Today, I’ll highlight the third and final publication, CGT Personas and User Stories , from this release of publications. As with the other two, Emerson’s Sean Buckley was one of the primary authors, along with others from Cytiva, Dassault Systems, Novartis…

  • BioPhorum Cell and Gene Therapy Personas and User Stories

    Jim Cahill
    Earlier I featured two recent BioPhorum publications in these posts: BioPhorum MES of the Future BioPhorum Cell and Gene Therapy Actors and Process Maps Today, I’ll highlight the third and final publication, CGT Personas and User Stories , from this release of publications. As with the other two, Emerson’s Sean Buckley was one of the primary authors, along with others from Cytiva, Dassault Systems, Novartis…

  • Shorten the Equipment Validation Process to Bring Projects Online Faster

    Jim Cahill
    One of the key stages delaying and increasing costs in life sciences projects is equipment validation. In fact, it is one of the elements of project completion that project teams are most eager to compress because the value of every incremental improvement is so great. As Michalle Adkins explains in her recent article in Pharma Manufacturing , “Ultimately, the total cost and time of the full validation process can be…

  • Shorten the Equipment Validation Process to Bring Projects Online Faster

    Jim Cahill
    One of the key stages delaying and increasing costs in life sciences projects is equipment validation. In fact, it is one of the elements of project completion that project teams are most eager to compress because the value of every incremental improvement is so great. As Michalle Adkins explains in her recent article in Pharma Manufacturing , “Ultimately, the total cost and time of the full validation process can be…

  • Shorten the Equipment Validation Process to Bring Projects Online Faster

    Jim Cahill
    One of the key stages delaying and increasing costs in life sciences projects is equipment validation. In fact, it is one of the elements of project completion that project teams are most eager to compress because the value of every incremental improvement is so great. As Michalle Adkins explains in her recent article in Pharma Manufacturing , “Ultimately, the total cost and time of the full validation process can be…

  • BioPhorum Cell and Gene Therapy Actors and Process Maps

    Jim Cahill
    A few weeks ago I highlighted one of the three new BioPhorum publications, MES of the Future Manifesto . Today, I’ll highlight a second one, CGT [cell & gene therapy] Actors and Process Maps . Emerson’s Sean Buckley was one of the authors along with co-authors from Roche, Takeda, and BioPhorum. Contributions were made during this Cell and Gene Therapy workstream from numerous biopharmaceutical manufacturers and software…

  • Is the Biotech Industry Growing?

    Jim Cahill
    In the biotech realm, many struggle to find experienced and technically savvy providers who can provide unique solutions in control automation. As trends accelerate in the biopharmaceutical industry, manufacturers are looking for new and improved approaches to address industry challenges. What role does Emerson play? Explore Emerson’s Single-Use Technologies to learn how Emerson offers control systems that save…

  • Is the Biotech Industry Growing?

    Jim Cahill
    In the biotech realm, many struggle to find experienced and technically savvy providers who can provide unique solutions in control automation. As trends accelerate in the biopharmaceutical industry, manufacturers are looking for new and improved approaches to address industry challenges. What role does Emerson play? Explore Emerson’s Single-Use Technologies to learn how Emerson offers control systems that save…

  • BioPhorum MES of the Future

    Jim Cahill
    We’ve highlighted the work of Emerson experts in the Biophorum Operations Group in several posts . Its mission: …is to create environments where the global biopharmaceutical industry can collaborate and accelerate its rate of progress, for the benefit of all. Emerson’s Sean Buckley alerted me to three recently published documents that he helped develop. These documents include: MES of the Future Manifesto CGT…

This is the official online community site of the Emerson Exchange, a forum for the free exchange of non-proprietary information among the global user community of all Emerson's products and services. Our goal is to improve the efficiency and use of automation systems and solutions employed at members’ facilities by sharing our knowledge, experiences, and application information.

Community Guidelines | Legal Information | Privacy Policy | Contact Community Manager

Website translation provided by Website Translator

© 2015-2026 Emerson Exchange. All rights reserved.